AIDS MALIGNANCY CONSORTIUM

这份加入艾滋病恶性肿瘤联盟的申请由 Joseph A. Sparano 博士代表 Montefiore 医疗中心（包括 Moses 分部和 Weiler 分部）以及其他四个机构组成的联盟提交，其中包括 Jacobi 医疗中心、北中央布朗克斯医院、布朗克斯黎巴嫩医院和长岛犹太医疗中心。 过去 8 年里，仅在 Montefiore 医疗中心 (MMC)，就有 111 名 HIV 相关恶性肿瘤患者在 Sparano 博士的指导下参加了临床试验。 布朗克斯区的艾滋病毒感染率是全国最高的，该社区由该联盟六家医院中的五家提供服务。在布朗克斯区的 120 万居民中，估计约有 30,000 人有意 (16,000) 或无意 (14,000) 感染了 HIV。 该社区不仅由医院内的 HIV 专科护理诊所提供服务，还由 MMC 或布朗克斯黎巴嫩医院 (BLH) 附属的 30 多个社区诊所提供服务。 BLH 还拥有积极的社区外展计划。 大约 5900 名患者接受联盟机构的初级艾滋病毒护理。 此外，据联盟机构估计，每年约有110名新诊断出艾滋病毒相关癌症和艾滋病相关癌症的患者，其中包括46名全身性淋巴瘤患者、14名原发性中枢神经系统淋巴瘤患者和50名卡波西肉瘤患者。 MMC 在癌症和艾滋病研究的临床试验方面拥有丰富的经验。 它是阿尔伯特·爱因斯坦医学院 (AECOM) 的大学医院，因此是 AECOM 指定的 NCI 综合癌症中心的临床部门。 每年，超过 100 个临床方案正在实施，超过 400 名患者参加临床试验，其中约 55% 的患者是非裔美国人或拉丁裔。 MMC 也是东部肿瘤合作组的成员。 1997年ECOG对MMC临床试验表现和数据管理的最后一次审核中，MMC被ECOG评为优秀至优秀。 纽约州指定的艾滋病中心设在 MMC 和 BLH，并且 MMC、BLH 和 Jacobi 医疗中心参加了 CPRA。 因此，MMC 及其合作伙伴非常适合成为 AMC 富有成效的成员，因为其庞大的患者基础、在癌症临床试验方面的丰富经验以及其主要研究者所展现的科学领导力。

This application for membership in the AIDS Malignancy Consortium is submitted by Dr. Joseph A. Sparano on behalf of Montefiore Medical Center (including the Moses Division and Weiler Division) and a consortium of four other institutions, including Jacobi Medical Center, North Central Bronx Hospital, Bronx Lebanon Hospital, and Long Island Jewish Medical Center. At Montefiore Medical Center (MMC) alone, 111 patients with HIV-associated malignancies have been enrolled on clinical trials under Dr. Sparano s direction over the past 8 years. The prevalence of HIV infection in the Bronx, the community served by five of the six hospitals in this consortium, is among the highest in the nation. Of the 1.2 million residents of the Bronx, it is estimated that about 30,000 are knowingly (16,000) or unknowingly (14,000) HIV- infected. This community is served not only by hospital-based HIV specialty care clinics, but also by over 30 community-based clinics affiliated with MMC or Bronx Lebanon Hospital (BLH). BLH also has an active community outreach program. Approximately 5900 patients receive primary HIV care by the consortium institutions. Moreover, among consortium institutions, it is estimated that each year there are approximately 110 patients newly diagnosed with HIV-associated and AIDS-associated cancers each year, including 46 patients wit systemic lymphoma, 14 patients with primary CNS lymphoma, and 50 patients with Kaposi s sarcoma. MMC has extensive experience in clinical trials in cancer and AIDS research. It is the University Hospital of the Albert Einstein College of Medicine (AECOM), and as such is the clinical arm of the NCI-designated Comprehensive Cancer Center at AECOM. Each year, over 100 clinical protocols are active, over 400 patients are enrolled on clinical trials, and about 55 percent of those enrolled on clinical trials are either African- American or Latino. MMC is also a member of the Eastern Cooperative Oncology Group. At ECOG s last audit of MMC s clinical trials performance and data management in 1997, MMC was rated as excellent to outstanding by ECOG. New York State- designated AIDS centers are based at MMC and BLH, and MMC, BLH, and Jacobi Medical Center participate in the CPCRA. MMC and its partners are therefore ideally suited to become productive members of AMC because of its large patient base, its considerable experience in cancer clinical trials, and the scientific leadership that has been demonstrated by its principal investigator.